Suppr超能文献

一种新型吞咽与呼吸感觉评估及一种用于减少慢性阻塞性肺疾病急性加重的模拟干预措施的成本效益。

Cost effectiveness of a novel swallowing and respiratory sensation assessment and a modelled intervention to reduce acute exacerbations of COPD.

作者信息

Epiu Isabella, Jenkins Christine R, Bulamu Norma B, Kuznik Andreas

机构信息

Prince of Wales clinical School, The University of New South Wales, Sydney, NSW, 2052, Australia.

Kabale University School of Medicine, Kabale, Uganda.

出版信息

BMC Pulm Med. 2025 Apr 9;25(1):165. doi: 10.1186/s12890-025-03615-y.

Abstract

Swallowing impairment observed in ~ 20% of people with Chronic Obstructive Pulmonary Disease (COPD) may increase the risk of aspiration pneumonia and acute exacerbations. We designed a decision analytic model to assess the cost-effectiveness of the Swallowing and Respiratory Sensation Assessment (SwaRSA) tests and swallowing rehabilitation to reduce COPD exacerbations. We believe that swallowing rehabilitation to improve coordination of swallowing and breathing may reduce exacerbations in people with COPD.From the Australia health system perspective, we assessed the cost effectiveness of four tests relative to standard of care, or no testing, over a time horizon of one year. The SwaRSA tests assessed relative to a standard of care arm of no testing: included the Eating Assessment Tool (EAT-10) score, Swallowing Capacity of Liquids, Tongue Strength Assessment, and Respiratory Sensation Assessment, in people with moderate to severe COPD. Outcome measures were COPD exacerbations per year, which were converted into quality adjusted life years (QALYs). Model inputs including costs, test sensitivities and specificities, COPD exacerbation risks, and exacerbation-related utilities were derived from published sources. Our assumptions on the costs, recovery, and risk reduction are based on the available data on pulmonary rehabilitation in COPD.Relative to no-SwaRSA, three individual testing strategies were found to be cost-effective at incremental cost effectiveness ratio per QALY ranging from $27,000 to $37,000 AUD assuming a willingness to pay of $50,000 AUD. The EAT-10 and the tongue strength were the two dominant options on the cost-effectiveness frontier. Model results were robust to variations in one-way and probabilistic sensitivity analyses.In COPD, SwaRSA modelling suggests that self-assessment with the EAT-10 and subsequent intervention is highly cost-effective relative to no-SwaRSA.

摘要

在约20%的慢性阻塞性肺疾病(COPD)患者中观察到的吞咽障碍可能会增加误吸性肺炎和急性加重的风险。我们设计了一个决策分析模型,以评估吞咽与呼吸感觉评估(SwaRSA)测试及吞咽康复治疗在降低COPD急性加重方面的成本效益。我们认为,通过吞咽康复来改善吞咽与呼吸的协调性可能会减少COPD患者的急性加重情况。从澳大利亚卫生系统的角度出发,我们在一年的时间范围内评估了四种测试相对于标准治疗或不进行测试的成本效益。相对于不进行测试的标准治疗组,SwaRSA测试评估了中重度COPD患者的以下指标:饮食评估工具(EAT - 10)评分、液体吞咽能力、舌肌力评估和呼吸感觉评估。结局指标为每年的COPD急性加重次数,这些次数被转换为质量调整生命年(QALYs)。模型输入数据包括成本、测试敏感度和特异度、COPD急性加重风险以及与急性加重相关的效用值,均来源于已发表的资料。我们对成本、恢复情况和风险降低的假设基于COPD肺康复的现有数据。相对于不进行SwaRSA测试,在假设支付意愿为50,000澳元的情况下,发现三种单独的测试策略具有成本效益,每QALY的增量成本效益比在27,000至37,000澳元之间。EAT - 10和舌肌力是成本效益前沿上的两个主要选项。模型结果在单向和概率敏感性分析的变化中具有稳健性。在COPD中,SwaRSA模型表明,相对于不进行SwaRSA测试,使用EAT - 10进行自我评估并随后进行干预具有很高的成本效益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/970b/11980303/346e55b9953e/12890_2025_3615_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验